RxDoctor Payments Data

Michael Nielson, DO

Family Medicine · Monticello, UTNPI 1700225679

Payments from drug & device makers

$395in general payments, 2019–2025

Across 18 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$182
  • AstraZeneca$93
  • Organon$30
  • Merck$27
  • Roche Diagnostics Corporation$17
  • Solventum Corporation$17
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$395100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$395 in reported general payments places this provider in the 50th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$3,291
Medicare patients
11
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban38$33,124
OzempicSemaglutide29$32,304
EliquisApixaban24$22,960
MounjaroTirzepatide16$16,504
Tresiba Flextouch U-200Insulin Degludec11$12,605
Tresiba Flextouch U-100Insulin Degludec14$8,237
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,185
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,639
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,055
Breo ElliptaFluticasone/Vilanterol12$4,597
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,696
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,979
Bumetanide19$2,164
Humalog Kwikpen U-100Insulin Lispro13$1,914
Potassium Chloride82$1,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$22,96024 claims
AstraZenecaBreztri Aerosphere$93$8,18513 claims
AbbVieSynthroid$182$1,32425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 928 family medicine providers in Utah.

Other family medicine in Monticello

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →